Search

Your search keyword '"Traboulsee, Anthony"' showing total 603 results
Start Over Author "Traboulsee, Anthony" Language english
603 results on '"Traboulsee, Anthony"'

4. Cortical morphology predicts placebo response in multiple sclerosis

Author

Cherkasova, Mariya V., Fu, Jessie F., Jarrett, Michael, Johnson, Poljanka, Abel, Shawna, Tam, Roger, Rauscher, Alexander, Sossi, Vesna, Kolind, Shannon, Li, David K. B., Sadovnick, A. Dessa, Machan, Lindsay, Girard, J. Marc, Emond, Francois, Vosoughi, Reza, Traboulsee, Anthony, and Stoessl, A. Jon

Published
2022
Full Text
View/download PDF

5. Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.

Author

Scalfari, Antonio, Traboulsee, Anthony, Oh, Jiwon, Airas, Laura, Bittner, Stefan, Calabrese, Massimiliano, Garcia Dominguez, Jose Manuel, Granziera, Cristina, Greenberg, Benjamin, Hellwig, Kerstin, Illes, Zsolt, Lycke, Jan, Popescu, Veronica, Bagnato, Francesca, and Giovannoni, Gavin

Subjects
*CEREBROSPINAL fluid, *MULTIPLE sclerosis, *PATIENTS' attitudes, *DRUG target, *CLINICAL trials
Abstract

Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often experience subtle deterioration, which extends beyond the definition of "progression independent of relapsing activity." We propose the concept of smouldering‐associated‐worsening (SAW), encompassing physical and cognitive symptoms, resulting from smouldering pathological processes, which remain unmet therapeutic targets. We provide a consensus‐based framework of possible pathological substrates and manifestations of smouldering MS, and we discuss clinical, radiological, and serum/cerebrospinal fluid biomarkers for potentially monitoring SAW. Finally, we share considerations for optimizing disease surveillance and implications for clinical trials to promote the integration of smouldering MS into routine practice and future research efforts. ANN NEUROL 2024;96:826–845 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics.

Author

Oh, Jiwon, Arbour, Nathalie, Giuliani, Fabrizio, Guenette, Melanie, Kolind, Shannon, Lynd, Larry, Marrie, Ruth Ann, Metz, Luanne M., Prat, Alexandre, Schabas, Alice, Smyth, Penelope, Tam, Roger, Traboulsee, Anthony, Yong, Voon Wee, and Patten, Scott B.

Subjects
MULTIPLE sclerosis, LONGITUDINAL method, COHORT analysis, INTELLECTUAL disabilities, CERVICAL cord, MAGNETIC resonance imaging, SPINAL cord injuries
Abstract

Background: Disease progression is observed across the spectrum of people with multiple sclerosis (MS) and identification of effective treatment strategies to halt progression remains one of the greatest unmet clinical needs. Objectives: The Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) was designed to evaluate a wide range of factors associated with the onset and rate of clinical disease progression in MS and to describe the interplay between these factors. Design: A prospective cohort study. Methods: CanProCo is a national, prospective, observational cohort study that has recruited 944 individuals from 5 large academic MS centers in Canada. Participants include people with radiologically isolated syndrome (RIS), early relapsing-remitting and primary progressive MS (RRMS, PPMS), and healthy controls (HCs). Annually, participants complete self-reported questionnaires, undergo clinical evaluation and, if clinically indicated, magnetic resonance images (MRIs) of the brain and cervical spinal cord; in a subset of participants (n = 399), blood, and research MRIs of the brain and cervical spinal cord are collected. Linkages to health administrative databases are available at three sites. Results: Overall, 944 participants were recruited (53 HCs, 63 RIS, 751 RRMS, 77 PPMS). RIS and MS participants had a mean age of 39.0 years and 70.5% female. The mean time since diagnosis was 2.7 years. There were differences observed in the Expanded Disability Status Scale score and components of the MS performance test (walking speed test, manual dexterity test, processing speed test, and low-contrast visual acuity) between RIS and MS subtypes. Questionnaires revealed more symptoms of depression and anxiety and impaired physical and mental quality of life in people with RIS/MS versus HCs and differences across RIS/MS subtypes. Conclusion: Physical and mental neurological disability is prevalent even in the earliest stages of MS. Transdisciplinary approaches such as those used in CanProCo are needed to better characterize clinical progression in MS. Additional CanProCo results, including MRI, biological, and pharmaco-economic data will be forthcoming. Going forward, CanProCo's data sharing and collaborative vision will facilitate numerous global collaborations, which will inform the development and implementation of effective interventions for people with MS around the world. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Myelin-oligodendrocyte glycoprotein antibody-associated disease

Author

Marignier, Romain, Hacohen, Yael, Cobo-Calvo, Alvaro, Pröbstel, Anne-Katrin, Aktas, Orhan, Alexopoulos, Harry, Amato, Maria-Pia, Asgari, Nasrin, Banwell, Brenda, Bennett, Jeffrey, Brilot, Fabienne, Capobianco, Marco, Chitnis, Tanuja, Ciccarelli, Olga, Deiva, Kumaran, De Sèze, Jérôme, Fujihara, Kazuo, Jacob, Anu, Kim, Ho Jin, Kleiter, Ingo, Lassmann, Hans, Leite, Maria-Isabel, Linington, Christopher, Meinl, Edgar, Palace, Jacqueline, Paul, Friedemann, Petzold, Axel, Pittock, Sean, Reindl, Markus, Sato, Douglas Kazutoshi, Selmaj, Krzysztof, Siva, Aksel, Stankoff, Bruno, Tintore, Mar, Traboulsee, Anthony, Waters, Patrick, Waubant, Emmanuelle, Weinshenker, Brian, Derfuss, Tobias, Vukusic, Sandra, and Hemmer, Bernhard

Published
2021
Full Text
View/download PDF

9. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Author

Grand'Maison, Francois, Jacques, Francois, Traboulsee, Anthony, Tyblova, Michaela, Meluzinova, Eva, Ampapa, Radek, Valis, Martin, Hradilke, Pavel, Mareš, Miroslav, Stourac, Pavel, Gross-Paju, Katrin, Laplaud, David, Mathey, Guillaume, Uitdehaag, Bernard, Evdoshenkoo, Evgeny, Popova, Ekaterina, Zakharova, Maria, Totolyan, Natalia, Litvinenko, Igor, Khabirov, Farit, Sivertseva, Stella, Hancinova, Viera, Kantorova, Ema, Gines, Maria Luisa Martinez, Montalban, Xavier, Maduano, Sara Eichau, Meca-Lallana, Jose, Ramió-Torrentà, Lluís, Nehrych, Tetyanna, Pashkovskyy, Valeriy, Moskovko, Sergii, Kalbus, Oleksandr, Khavunka, Marta, Pryshchepa, Volodymyr, Goloborodko, Alla, Wynn, Daniel, Honeycutt, William, Wray, Sibyl, Steingo, Brian, LaGanke, Christopher, Huang, Deren, Hemphill, John Michael, Goldstick, Lawrence, Robertson, Derrick, Reich, Daniel S, Arnold, Douglas L, Vermersch, Patrick, Bar-Or, Amit, Fox, Robert J, Matta, Andre, Turner, Timothy, Wallström, Erik, Zhang, Xinyan, and Khabirov, Farit A

Published
2021
Full Text
View/download PDF

11. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

Author

Wattjes, Mike P, Ciccarelli, Olga, de Stefano, Nicola, Enzinger, Christian, Fazekas, Franz, Filippi, Massimo, Frederiksen, Jette, Gasperini, Claudio, Hacohen, Yael, Kappos, Ludwig, Mankad, Kshitij, Montalban, Xavier, Palace, Jacqueline, Rocca, María A, Sastre-Garriga, Jaume, Tintore, Mar, Vrenken, Hugo, Yousry, Tarek, Barkhof, Frederik, Rovira, Alex, Li, David K B, Traboulsee, Anthony, Newsome, Scott D, Banwell, Brenda, Oh, Jiwon, Reich, Daniel S, Rocca, Maria A, Tintoré, Mar, and Rovira, Àlex

Published
2021
Full Text
View/download PDF

12. Pooled analysis of multiple sclerosis findings on multisite 7 Tesla MRI: Protocol and initial observations.

Author

Harrison, Daniel M., Choi, Seongjin, Bakshi, Rohit, Beck, Erin S., Callen, Alexis M., Chu, Renxin, Silva, Jonadab Dos Santos, Fetco, Dumitru, Greenwald, Matthew, Kolind, Shannon, Narayanan, Sridar, Okar, Serhat V., Quattrucci, Molly K., Reich, Daniel S., Rudko, David, Russell‐Schulz, Bretta, Schindler, Matthew K., Tauhid, Shahamat, Traboulsee, Anthony, and Vavasour, Zachary

Subjects
DATA libraries, IMAGE processing, DATA harmonization, GRAY matter (Nerve tissue), MULTIPLE sclerosis
Abstract

Although 7 T MRI research has contributed much to our understanding of multiple sclerosis (MS) pathology, most prior data has come from small, single‐center studies with varying methods. In order to truly know if such findings have widespread applicability, multicenter methods and studies are needed. To address this, members of the North American Imaging in MS (NAIMS) Cooperative worked together to create a multicenter collaborative study of 7 T MRI in MS. In this manuscript, we describe the methods we have developed for the purpose of pooling together a large, retrospective dataset of 7 T MRIs acquired in multiple MS studies at five institutions. To date, this group has contributed five‐hundred and twenty‐eight 7 T MRI scans from 350 individuals with MS to a common data repository, with plans to continue to increase this sample size in the coming years. We have developed unified methods for image processing for data harmonization and lesion identification/segmentation. We report here our initial observations on intersite differences in acquisition, which includes site/device differences in brain coverage and image quality. We also report on the development of our methods and training of image evaluators, which resulted in median Dice Similarity Coefficients for trained raters' annotation of cortical and deep gray matter lesions, paramagnetic rim lesions, and meningeal enhancement between 0.73 and 0.82 compared to final consensus masks. We expect this publication to act as a resource for other investigators aiming to combine multicenter 7 T MRI datasets for the study of MS, in addition to providing a methodological reference for all future analysis projects to stem from the development of this dataset. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Author

Amato, Maria Pia, Banwell, Brenda, Barkhof, Frederik, Bebo, Bruce, Becher, Burkhard, Bethoux, François, Brandt, Alexander, Brownlee, Wallace, Calabresi, Peter, Chatway, Jeremy, Chien, Claudia, Chitnis, Tanuja, Ciccarelli, Olga, Cohen, Jeffrey, Comi, Giancarlo, Correale, Jorge, De Sèze, Jerome, De Stefano, Nicola, Fazekas, Franz, Flanagan, Eoin, Freedman, Mark, Fujihara, Kazuo, Galetta, Steven, Goldman, Myla, Greenberg, Benjamin, Hartung, Hans-Peter, Hemmer, Bernhard, Henning, Anke, Izbudak, Izlem, Kappos, Ludwig, Lassmann, Hans, Laule, Cornelia, Levy, Michael, Lublin, Fred, Lucchinetti, Claudia, Lukas, Carsten, Marrie, Ruth Ann, Miller, Aaron, Miller, David, Montalban, Xavier, Mowry, Ellen, Ourselin, Sebastien, Paul, Friedemann, Pelletier, Daniel, Ranjeva, Jean-Philippe, Reich, Daniel, Reingold, Stephen, Rocca, Maria Assunta, Rovira, Alex, Schlaerger, Regina, Soelberg Sorensen, Per, Sormani, Maria, Stuve, Olaf, Thompson, Alan, Tintoré, Mar, Traboulsee, Anthony, Trapp, Bruce, Trojano, Maria, Uitdehaag, Bernard, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian, Wheeler-Kingshott, Claudia Gandini, Xu, Junqian, Cohen, Jeffrey A, Reingold, Stephen C, and Weinshenker, Brian G

Published
2019
Full Text
View/download PDF

20. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

Author

Correale, Jorge, Caride, Alejandro, Deri, Norma H., Ballario, Carlos, Broadley, Simon, Kneebone, Chris, Barnett, Michael, Pollard, John, Hodgkinson, Suzanne, Kermode, Allan, Macdonell, Richard, King, John, Butzkueven, Helmut, Lechner-Scott, Jeannette, Saines, Noel, Slee, Mark, Plummer, Chris, Willekens, Barbara, Vanopdenbosch, Ludo, Belachew, Shibeshih, Phan-Ba, Rémy, Delvaux, Valérie, Bissay, Veronique, Debruyne, Jan, Decoo, Danny, Crols, Roeland, Symons, Anoek, Nagels, Guy, Van Pesch, Vincent, Sindic, Christian, Dubois, Benedicte, Medaer, Robert, D'Hooghe, Marie, Guillaume, Daniel, De Smet, Eric, Seeldrayers, Pierrette, Lysandropoulos, Andreas, Vokaer, Mathieu, Geens, Karine, Willems, Christina, Denayer, Pierre, Bureau, Michel, Retif, Cecile, Dupuis, Michel, Bouquiaux, Olivier, Vanderdonckt, Patrick, van Landegem, William, Caekebeke, Jo, Van Ingelghem, Erwin, Peeters, Katelijne, Gerard, Pascale, de Noordhout, Alain Maertens, Desfontaines, Philippe, Urbain, Etienne, Declercq, Inge, Van Wijmeersch, Bart, Vanroose, Erwin, Wibail, Alain, Barthomolé, Emmanuel, Ursell, Melanie, Sweet, Margaret Elizabeth, Howse, David, Jichici, Draga, Shawush, Melad, Namaka, Mike, Traboulsee, Anthony, Hashimoto, Stan, Lo, Raymond, Marchetti, Paul, Lapierre, Yves, Jacques, Francois, MacLean, Gregg, Bhan, Virender, Duquette, Pierre, Stewart, Bradley, Paulseth, John, Kremenchutzky, Marcelo, Vorobeychik, Galina, O'Connor, Paul, Grand'Maison, François, Havrdova, Eva, Meluzinová, Eva, Valis, Martin, Talab, Radomír, Stourac, Pavel, Zapletalová, Olga, Dufek, Michal, Sládková, Vladimíra, Novotna, Alena, Vancurová, Romana, Lhotaková, Libuse, Fiedler, Jiri, Vachova, Marta, Dolezil, David, Stetkarova, Ivana, Rehankova, Adela, Psenica, Petr, Ulehlova, Veronika, Feketova, Sona, Skoda, Ondrej, Färkkilä, Markus, Taneli, Sarasoja, Koivisto, Keijo, Seppä, Juha Matti, Airas, Laura, Elovaara, Irina, Hartikainen, Päivi, Pirttila, Tuula, Louchart, Pierre, Ille, Olivier, Thenint, Jean philippe, Godet, Etienne, Vioud, Marcel Maillet, Colamarino, Renato, Gugenheim, Michel, Grimaud, Jerome, Kopf, Audrey, Billy, Christophe, Huttin, Bernard, Borsotti, Jean paul, Devos, Philippe, Kendjuo, Jean bertin N, Verier, Albert, Chapuis, Stephane, Daluzeau, Nathalie, Angibaud, Gilles, Uriot, Marie-Sylvie Artaud, Ziegler, François, Sellal, François, Moulignier, Antoine, Lavenu, Isabelle, Ismail, Samir, Devy, Richard, Suceveanu, Manuel, Wagner, Marc, Marcel, Sebastien, Derouiche, Faycal, Mostoufizadehghalamfarsa, Sohrab, Delalande, Sophie, Ruggieri, Irene, Van Nieuwenhuyse, Catherine Bossu, Nifle, Chantal, Ondze, Basile, Vasilescu, Carmen Gurau, Vongsouthi, Cyrille, Coustans, Marc, Anne, Olivier, Amevigbe, Josephine, Servan, Jerome, Merienne, Marc, Eck, Philippe, Berroir, Stephane, Busson, Philippe, Barroso, Bruno, Larrieu, Jean-Marc, Giendaj, Catherine Louvet, Malkoun, Imad, Hautecoeur, Patrick, Kwiatkowski, Arnaud, Pouliquen, Andre, Garrigues, Guillaume, Delerue, Olivier, Giraud, Pierric, Gere, Julien, Vaunaize, Jean, Dereeper, Olivier, Seiller, Nicolas, Alsassa, Roger, Vlaicu, Mihaela, Neuville, Veronique, Faucheux, Jean Marc, Bernady, Patricia, Fanjaud, Guy, Viallet, François, Schroeter, Michael, Schlemilch-Paschen, Sylke, Lange, Thomas, Bohr, Kin-Arno, Jendroska, Klaus, Rehkopf, Elisabeth, Bergmann, Arnfin, Kleinschnitz, Christoph, Postert, Thomas, Scholz, Peter, Mauz, Uwe, Stratmann, Hubert, Siefjediers, Veneta, Prantl, Martin, Gehring, Klaus, Zellner, Ruth, Junge, Kathrin, Zellner, Anton, Bacay, Valerina, Schlegel, Eugen, Polzer, Udo, Strauss, Erik, Link, Andreas, Stenzel, Christoph, Freidel, Matthias, Drews, Joachim, Neudert, Christian, Schmitz, Frank, Jaeger, Joachim, Masri, Said, Heuberger, Wolfgang, Trausch, Beate, Ruhnke, Oliver, Scarel, Serena, Bach, Kathlen, Ernst, Michael, Landefeld, Harald, Richter, Nils, Schmidt, Stephan, Krause, Michaela, Dressel, Alezander, Ruth, Roland, Anvari, Kerstin, Gossling, Jens, Schenk, Christoph, Tiedge, Oliver, Bode, Lutz, Eder, Hans-Thomas, Pfeffer, Oliver, Krug, Reinhard, Lassek, Christoph, Fleischer, Eberhard, Meuth, Sven, Klotz, Luisa Hildegard, Peglau, Ines, Kukowski, Borries, Herting, Birgit, Guthke, Kersten, Schierenbeck, Jurgen, Brockmeier, Bernd, Albrecht, Holger, Wuttke, Matthias, Augspach-Hofmann, Regine, Gunther, Stefan, Redbrake, Martin, Franke, Christian, Buchner, Klaus, Gratz, Thomas, Horn, Rolf, Doemges, Frank, Schreiber, Martin, Brosch, Thomas, Horn, Markus, Kittlitz, Matthias, Vulturius, Gabriele, Hinse, Paul, Malessa, Rolf, Wiehler, Stephan, Katsarava, Zaza, Kastrup, Oliver, Kausch, Ulrich, Gullekes, Martin, Fickinger, Markus, Wenzel, Wilhelm, Botefur, Ingolf C., Reifschneider, Gerd, Rauer, Sebastian, Lang, Michael, Harms, Lutz, Eckhardt, Ulrich, Cursiefen, Simone, Linker, Ralf, Angstwurm, Klemens, Haas, Judith, Schuetze, Ivo, Rohm, Eva, Stienker-Fisse, H., Sailer, Michael, Bohringer, Johannes, Maurer, Mathias, Bause, Eberhard, Wersching, Ronald, Dachsel, Reinhardt, Domke, Sylke, Hoffman, Frank, Tackenberg, Bjorn, Roch, Kerstin, Ziebold, Uwe, Kallmann, Boris, Buehler, Bernhard, Faiss, Judith, Faiss, Juergen, Schimrigk, Sebastian, Menges, Christian, Knop, Karl Christian, Koehler, Wolfgang, Siever, Arno, Bufler, Johannes, Gramsl, Georg, Kuhnler, Benedicta, Maschke, Matthias, Stogbauer, Florian, Staude, Lisa, Bethke, Florian, Bitsch, Andreas, Harmjanz, Arndt D., Windsheimer, Jorg, Kieseier, Bernd C., Berkenfeld, Ralf, Tumani, Hayrettin, Kirsch, Michael, Wildemann, Brigitte, Daniels, Regina, Gottwald, Klaus, Elias, Wolfgang-Gerhard, Hoffmann, Olaf, Schwab, Matthias, Pilz, Christopher, Klostermann, Fabian, Hellwig, Kerstin, Berthele, Achim, Bayas, Antonios, Molitor, Daniel, Grothe, Christoph, Wagner, Bert, Karageorgiou, Klimentini, Mitsikostas, Dimosthenis, Kodounis, Antonios, Plaitakis, Andreas, Papadimitriou, Alexandros, Grigoriadis, Nikolaos, Vlaikidis, Nikolaos, Koutlas, Evaggelos, Kyritsis, Athanassios, Papathanassopoulos, Panagiotis, Makris, Nikolaos, Tavernarakis, Antonios, Scarpini, Elio, Montanari, Enrico, Marrosu, Maria Giovanna, Trojano, Maria, Amato, Maria Pia, Rottoli, Mariarosa, Lugaresi, Alessandra, Florio, Ciro, Gasperini, Claudio, Grimaldi, Luigi, Millefiorini, Enrico, Koudriavtseva, Tatiana, Perla, Franco, Mantegazza, Renato, Bertolotto, Antonio, Ghezzi, Angelo, Aguilar, Sandra Quinones, Eisenberg, Eli Skromne, Lopez, Leondardo Llamas, Estudillo, Rocio Marquez, Schrijver, H.M., Wittebol, M.C., Baart, J.C., van Golde, A.E.L., Hengstman, G.J.D., Pop, P.H.M., Bos (Geldrop), M., Medaer, R., Schyns-Soeterboek, Angelique, van der Zwart, A., van Diepen, A.J.H., Verheul, G.A.M., Verhagen, W.I.M., Bos (Helmond), M., Witjes, R.J.G.M., Sinnige, L.G.F., van Munster, E.Th.L., Sanders, E.A.C.M., van Dijl, Ron, Hupperts, R.M.M., Frequin, S.T.F.M., Visser, L.H., Henselmans, J.M.L., Moll, J.W.B., Midgard, Rune, Myhr, Kjell Morten, Edland, Astrid, Telstad, Wenche, Hognestad, Tone, Lund, Christian, Hovdal, Harald, Kamaljit, Kaur, Schepel, Jan, Hogenesch, Roelfien Ida, Schüler, Stephan, Odeh, Francis, Alstadhaug, Karl B., Korsgaard, Olav, Farbu, Elisabeth, Ingvaldsen, Teis Barclay, Soares (SCO), Diana, Rente, José, Guerra, José Manuel Costa, Morganho, Armando, Leitão, António, de Sá, João, Sá, Maria José, Marques, Pinto, Veloso, Mário, Baptista, Miguel Viana, Szilasiová, Jarmila, Copikova-Cudrakova, Daniela, Prochazkova, Lubica, Klimová, Eleonóra, Donath, Vladimir, Brozman, Miroslav, Ramo, Cristina, Ruiz, Domingo Pérez, Hernández, Carmen Calles, Sola, María Eugenia Marzo, Moro, Roberto Suarez, Vidal, Jose Antonio, Rodríguez, Ana Belén Caminero, Ozaeta, Gisela Martin, Nadal, Jordi Batlle, Esquide, Amaya Alvarez de Arcaya, Urtaza, Javier Olascoaga, Martínez-Yélamos, Sergio, Arbizu, Txomin, Torrenta, Lluis Ramio i, Boggild, Mike, Wilson, Martin, Al-Araji, Adnan, Nicholas, Richard, Harrower, Timothy, Redmond, Ian, Wolf, Tilo, Osei-Bonsu, Michael, Mazibrada, Gordon, Rog, David, Cottrell, David, Constantinescu, Cris, Gray, Orla, Belhag, Mohamed, Shehu, Abdullah, Rashid, Waqar, Duddy, Martin, Kappos, Ludwig, Wiendl, Heinz, Spelman, Tim, Pellegrini, Fabio, Chen, Yi, Dong, Qunming, and Koendgen, Harold

Published
2018
Full Text
View/download PDF

22. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Author

Thompson, Alan J, Banwell, Brenda L, Barkhof, Frederik, Carroll, William M, Coetzee, Timothy, Comi, Giancarlo, Correale, Jorge, Fazekas, Franz, Filippi, Massimo, Freedman, Mark S, Fujihara, Kazuo, Galetta, Steven L, Hartung, Hans Peter, Kappos, Ludwig, Lublin, Fred D, Marrie, Ruth Ann, Miller, Aaron E, Miller, David H, Montalban, Xavier, Mowry, Ellen M, Sorensen, Per Soelberg, Tintoré, Mar, Traboulsee, Anthony L, Trojano, Maria, Uitdehaag, Bernard M J, Vukusic, Sandra, Waubant, Emmanuelle, Weinshenker, Brian G, Reingold, Stephen C, and Cohen, Jeffrey A

Published
2018
Full Text
View/download PDF

26. Prevalence of Extracranial Venous Narrowing on Magnetic Resonance Venography Is Similar in People With Multiple Sclerosis, Their Siblings, and Unrelated Healthy Controls: A Blinded, Case-Control Study

Author

Martin, Nancy, Traboulsee, Anthony L., Machan, Lindsay, Klass, Darren, Ellchuk, Tasha, Zhao, Yinshan, Knox, Katherine B., Kopriva, David, Lala, Shantilal, Nickel, Darren, Otani, Robert, Perera, Warren R., Rauscher, Alexander, Sadovnick, A. Dessa, Szkup, Peter, and Li, David K.

Published
2017
Full Text
View/download PDF

29. Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD

Author

Cook, Lawrence J., Rose, John W., Alvey, Jessica S., Jolley, Anna Marie, Kuhn, Renee, Marron, Brie, Pederson, Melissa, Enriquez, Rene, Yearley, Jeff, McKechnie, Stephen, Han, May H., Tomczak, Anna J., Levy, Michael, Mealy, Maureen A., Coleman, Jessica, Bennett, Jeffrey L., Johnson, Ruth, Barnes-Garcia, Myka, Traboulsee, Anthony L., Carruthers, Robert L., Lee, Lisa Eunyoung, Schubert, Julia J., McMullen, Katrina, Kister, Ilya, Rimler, Zoe, Reid, Allyson, Sicotte, Nancy L., Planchon, Sarah M., Cohen, Jeffrey A., Ivancic, Diane, Sedlak, Jennifer L., Sand, Ilana Katz, Repovic, Pavle, Amezcua, Lilyana, Pruitt, Ana, Amundson, Erika, Chitnis, Tanuja, Mullin, Devin S., Klawiter, Eric C., Russo, Andrew W., Riley, Claire S., Onomichi, Kaho B., Levine, Libby, Nelson, Katherine E., Nealon, Nancy M., Engel, Casey, Kruse-Hoyer, Mason, Marcille, Melanie, Tornes, Leticia, Rumpf, Anne, Greer, Angela, Kenneally Behne, Megan, Rodriguez, Renee R., Behne, Daniel W., Blackway, Derek W., Coords, Brian, Blaschke, Terrence F., Sheard, Judy, Smith, Terry J., Behne, Jacinta M., and Yeaman, Michael R.

Published
2019
Full Text
View/download PDF

30. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis

Author

Kowalec, Kaarina, Wright, Galen E. B., Drögemöller, Britt I., Aminkeng, Folefac, Bhavsar, Amit P., Kingwell, Elaine, Yoshida, Eric M., Traboulsee, Anthony, Marrie, Ruth Ann, Kremenchutzky, Marcelo, Campbell, Trudy L., Duquette, Pierre, Chalasani, Naga, Wadelius, Mia, Hallberg, Pär, Xia, Zongqi, De Jager, Philip L., Denny, Joshua C., Davis, Mary F., Ross, Colin J. D., Tremlett, Helen, and Carleton, Bruce C.

Published
2018
Full Text
View/download PDF

35. Imaging outcome measures of neuroprotection and repair in MS: A consensus statement from NAIMS

Author

Oh, Jiwon, Ontaneda, Daniel, Azevedo, Christina, Klawiter, Eric C., Absinta, Martina, Arnold, Douglas L., Bakshi, Rohit, Calabresi, Peter A., Crainiceanu, Ciprian, Dewey, Blake, Freeman, Leorah, Gauthier, Susan, Henry, Roland, Inglese, Mathilde, Kolind, Shannon, Li, David K.B., Mainero, Caterina, Menon, Ravi S., Nair, Govind, Narayanan, Sridar, Nelson, Flavia, Pelletier, Daniel, Rauscher, Alexander, Rooney, William, Sati, Pascal, Schwartz, Daniel, Shinohara, Russell T., Tagge, Ian, Traboulsee, Anthony, Wang, Yi, Yoo, Youngjin, Yousry, Tarek, Zhang, Yunyan, Sicotte, Nancy L., and Reich, Daniel S.

Published
2019
Full Text
View/download PDF

38. Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study.

Author

Coles, Alasdair J., Achiron, Anat, Traboulsee, Anthony, Singer, Barry A., Pozzilli, Carlo, Oreja-Guevara, Celia, Giovannoni, Gavin, Comi, Giancarlo, Freedman, Mark S., Ziemssen, Tjalf, Shiota, Debora, Rawlings, Andreea M., Wong, Alana T., Chirieac, Magdalena, and Montalban, Xavier

Subjects
ALEMTUZUMAB, MULTIPLE sclerosis, DISEASE relapse, CLINICAL trials, INTERFERONS
Abstract

Background and objectives: Alemtuzumab demonstrated superior efficacy versus subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy was maintained in the 4-year CARE-MS extension, during which alemtuzumab-treated participants ('alemtuzumab-only') could receive additional courses upon disease activity, and IFN-treated participants switched to alemtuzumab ('IFN-alemtuzumab'). Participants who completed the CARE-MS extension could enroll in the open-label TOPAZ study which assessed safety and efficacy for 5–7 years (11–13 years after alemtuzumab/IFN initiation). Methods: Participants received additional alemtuzumab courses as needed. Assessments included adverse events (AEs; primary outcome), annualized relapse rate (ARR), 6-month confirmed disability worsening [CDW; ⩾1.0-point Expanded Disability Status Scale (EDSS) score increase or ⩾1.5 if baseline EDSS = 0], and 6-month confirmed disease improvement [CDI; >1.0-point EDSS decrease (baseline score ⩾2.0)]. Results: 43.5% of alemtuzumab-only participants from CARE-MS II and 54.2% from CARE-MS I received no additional alemtuzumab courses; 30.0% and 20.9%, respectively, received one additional course (the median). Incidences of AEs, including thyroid AEs and infections, declined over time. The safety profile of alemtuzumab was similar for participants who received zero, one, or two additional courses. For CARE-MS II participants, who had inadequate response to previous treatment, ARR remained low during Years 3–13 for the alemtuzumab-only [0.17; 95% confidence interval (CI) 0.15–0.20] and IFN-alemtuzumab (0.14; 0.11–0.17) groups. At Year 11, the proportions of participants who were either free from CDW or who had CDI were higher in the alemtuzumab-only group (58% and 49%, respectively) than in the IFN-alemtuzumab group (51% and 37%). For CARE-MS I participants, who were previously treatment-naïve, clinical outcomes remained improved, and no between-group differences were apparent. Conclusion: Safety risks associated with alemtuzumab treatment declined over time. Clinical benefits were maintained up to 11–13 years, and most participants did not require more than one additional course. Clinicaltrials.gov identifiers: NCT00530348; NCT00548405; NCT00930553; NCT02255656 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Accounting for uncertainty in training data to improve machine learning performance in predicting new disease activity in early multiple sclerosis.

Author

Tayyab, Maryam, Metz, Luanne M., Li, David K. B., Kolind, Shannon, Carruthers, Robert, Traboulsee, Anthony, and Tam, Roger C.

Subjects
MACHINE learning, MACHINE performance, MULTIPLE sclerosis, RANDOM forest algorithms, FORECASTING
Abstract

Introduction: Machine learning (ML) has great potential for using health data to predict clinical outcomes in individual patients. Missing data are a common challenge in training ML algorithms, such as when subjects withdraw from a clinical study, leaving some samples with missing outcome labels. In this study, we have compared three ML models to determine whether accounting for label uncertainty can improve a model's predictions. Methods: We used a dataset from a completed phase-III clinical trial that evaluated the efficacy of minocycline for delaying the conversion from clinically isolated syndrome to multiple sclerosis (MS), using the McDonald 2005 diagnostic criteria. There were a total of 142 participants, and at the 2-year follow-up 81 had converted to MS, 29 remained stable, and 32 had uncertain outcomes. In a stratified 7-fold cross-validation, we trained three random forest (RF) ML models using MRI volumetric features and clinical variables to predict the conversion outcome, which represented new disease activity within 2 years of a first clinical demyelinating event. One RF was trained using subjects with the uncertain labels excluded (RFexclude), another RF was trained using the entire dataset but with assumed labels for the uncertain group (RFnaive), and a third, a probabilistic RF (PRF, a type of RF that can model label uncertainty) was trained on the entire dataset, with probabilistic labels assigned to the uncertain group. Results: Probabilistic random forest outperformed both the RF models with the highest AUC (0.76, compared to 0.69 for RFexclude and 0.71 for RFnaive) and F1-score (86.6% compared to 82.6% for RFexclude and 76.8% for RFnaive). Conclusion: Machine learning algorithms capable of modeling label uncertainty can improve predictive performance in datasets in which a substantial number of subjects have unknown outcomes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Employment status, productivity loss, and associated factors among people with multiple sclerosis.

Author

Rodriguez Llorian, Elisabet, Zhang, Wei, Khakban, Amir, Michaux, Kristina, Patten, Scott, Traboulsee, Anthony, Oh, Jiwon, Kolind, Shannon, Prat, Alexandre, Tam, Roger, and Lynd, Larry D

Subjects
MULTIPLE sclerosis, COGNITIVE processing speed, LABOR productivity, EMPLOYMENT, DISABILITIES
Abstract

Background: Multiple Sclerosis (MS) affects people in their most productive years of life. Consequently, MS can substantially affect employment and work-related outcomes. Objectives: This study characterizes productivity loss and employment status of people with multiple sclerosis (pwMS) and investigates associated factors. Methods: We used baseline data collected as part of the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). Using the Valuation of Lost Productivity questionnaire, we measured MS-related paid work productivity loss for those employed, productivity losses incurred by those unemployed (i.e. lost employment time), and unpaid work productivity losses for all. A set of sociodemographic, disease, and performance-related factors were investigated using a two-part regression model for productivity loss and a multinomial logistic model for employment status. Results: From the cohort of 888 pwMS enrolled at baseline (mostly showing mild to moderate disability), 75% were employed, and of those unemployed, 69% attributed their unemployment to health-related issues. Total productivity loss over a 3-month period averaged 64 and 395 hours for those employed and unemployed, respectively. Some factors that affected productivity loss and employment status included use of disease-modifying therapies, fatigue, and performance indicators such as cognitive processing speed. Conclusion: Productivity loss experienced by employed and unemployed pwMS is substantial. Targeting the identified modifiable factors is likely to improve work productivity and permanence of MS patients in the workforce. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results